Kevin’s Story: Living with Lambert-Eaton Myasthenic Syndrome
November 1, 2023
Meet Kevin, an Anovo patient living with Lambert-Eaton myasthenic syndrome. Despite the challenges he’s faced in not always being able to provide the way he could before his diagnosis or do all the things he wants to do on a daily basis, Kevin shares how a revolutionary therapy has transformed his life. Watch the video to hear Kevin talk about his journey and explain how Anovo stepped up to the plate to make sure he receives the care he deserves and in his own words “[has] not disappointed me one time.”
“Anovo has been a really good advocate for me through this whole process. I am really grateful for the team that I have. I feel that they have my back.”
Related Posts

How Anovo Builds Dedicated Teams to Support Your Rare Disease Therapy
At Anovo, we understand that complex rare disease therapies require high-touch service that large payer- and Pharmacy Benefit Manager-owned Specialty…
January 30, 2025

Justin’s Story: Living with Duchenne Muscular Dystrophy
When Justin was first diagnosed with Duchenne muscular dystrophy, his parents, Amanda and Andrew, weren’t sure how to navigate the…
January 14, 2025

Eton Pharmaceuticals & Anovo Partner to Expand Access for Patients with Severe Primary Insulin-Like Growth Factor 1 Deficiency
Eton Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases, with a strong focus on pediatric endocrinology. Their…
December 20, 2024